Three doses of BNT162b2 COVID-19 mRNA vaccine establish long-lasting CD8(+) T cell immunity in CLL and MDS patients

Patients with hematological malignancies are prioritized for COVID-19 vaccine due to their high risk for severe SARS-CoV-2 infection-related disease and mortality. To understand T cell immunity, its long-term persistence, and its correlation with antibody response, we evaluated the BNT162b2 COVID-19...

Descripción completa

Detalles Bibliográficos
Autores principales: Hernandez, Susana Patricia Amaya, Hersby, Ditte Stampe, Munk, Kamilla Kjærgaard, Tamhane, Tripti, Trubach, Darya, Tagliamonte, Maria, Buonaguro, Luigi, Gang, Anne Ortved, Hadrup, Sine Reker, Saini, Sunil Kumar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9873231/
https://www.ncbi.nlm.nih.gov/pubmed/36703960
http://dx.doi.org/10.3389/fimmu.2022.1035344

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9873231/
https://www.ncbi.nlm.nih.gov/pubmed/36703960
http://dx.doi.org/10.3389/fimmu.2022.1035344

Ejemplares similares